JP2017505285A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017505285A5 JP2017505285A5 JP2016532631A JP2016532631A JP2017505285A5 JP 2017505285 A5 JP2017505285 A5 JP 2017505285A5 JP 2016532631 A JP2016532631 A JP 2016532631A JP 2016532631 A JP2016532631 A JP 2016532631A JP 2017505285 A5 JP2017505285 A5 JP 2017505285A5
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic agent
- agent according
- salt
- compound
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003814 drug Substances 0.000 claims 13
- 229940124597 therapeutic agent Drugs 0.000 claims 13
- 150000001875 compounds Chemical class 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- JWHYSEDOYMYMNM-QGZVFWFLSA-N 2-[4-[(2r)-2-ethoxy-3-[4-(trifluoromethyl)phenoxy]propyl]sulfanyl-2-methylphenoxy]acetic acid Chemical group C([C@@H](OCC)CSC=1C=C(C)C(OCC(O)=O)=CC=1)OC1=CC=C(C(F)(F)F)C=C1 JWHYSEDOYMYMNM-QGZVFWFLSA-N 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 229940122392 PCSK9 inhibitor Drugs 0.000 claims 3
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 238000003786 synthesis reaction Methods 0.000 claims 2
- SBZKOWAPPRXYGA-XRIGFGBMSA-N (2s)-2,6-diaminohexanoic acid;dihydrate Chemical compound O.O.NCCCC[C@H](N)C(O)=O SBZKOWAPPRXYGA-XRIGFGBMSA-N 0.000 claims 1
- 208000000563 Hyperlipoproteinemia Type II Diseases 0.000 claims 1
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 claims 1
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 claims 1
- 229960002027 evolocumab Drugs 0.000 claims 1
- 201000001386 familial hypercholesterolemia Diseases 0.000 claims 1
Claims (13)
- （Ｒ）−２−（４−（（２−エトキシ−３−（４−（トリフルオロメチル）フェノキシ）プロピル）チオ）−２−メチルフェノキシ）酢酸である化合物またはその塩を含む、対象におけるホモ接合性家族性高コレステロール血症の治療剤。
- 前記化合物が、（Ｒ）−２−（４−（（２−エトキシ−３−（４−（トリフルオロメチル）フェノキシ）プロピル）チオ）−２−メチルフェノキシ）酢酸のＬ−リジン二水和物である、請求項１に記載の治療剤。
- 経口投与のための、請求項１または２に記載の治療剤。
- 前記化合物の用量が、（Ｒ）−２−（４−（（２−エトキシ−３−（４−（トリフルオロメチル）フェノキシ）プロピル）チオ）−２−メチルフェノキシ）酢酸として算出した場合、２０〜２００ｍｇ／日である、請求項１〜３のいずれか１項に記載の治療剤。
- 前記化合物の用量が、（Ｒ）−２−（４−（（２−エトキシ−３−（４−（トリフルオロメチル）フェノキシ）プロピル）チオ）−２−メチルフェノキシ）酢酸として算出した場合、５０〜２００ｍｇ／日である、請求項４に記載の治療剤。
- 前記化合物が、１日１回投与されるものである、請求項１〜５のいずれか１項に記載の治療剤。
- 前記対象が、ＭＴＰ阻害剤も投与されるものである、請求項１〜６のいずれか１項に記載の治療剤。
- 前記ＭＴＰ阻害剤が、ロミタピドまたはその塩である、請求項７に記載の治療剤。
- 前記対象が、ａｐｏＢ−１００合成阻害剤も投与されるものである、請求項１〜６のいずれか１項に記載の治療剤。
- 前記ａｐｏＢ−１００合成阻害剤が、ミポメルセンまたはその塩である、請求項９に記載の治療剤。
- 前記対象が、ＰＣＳＫ９阻害剤も投与されるものである、請求項１〜６のいずれか１項に記載の治療剤。
- 前記ＰＣＳＫ９阻害剤が、エボロクマブまたはその塩である、請求項１１に記載の治療剤。
- 前記ＰＣＳＫ９阻害剤が、アリロクマブまたはその塩である、請求項１１に記載の治療剤。
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361906837P | 2013-11-20 | 2013-11-20 | |
| US61/906,837 | 2013-11-20 | ||
| US201461942438P | 2014-02-20 | 2014-02-20 | |
| US61/942,438 | 2014-02-20 | ||
| US201461942941P | 2014-02-21 | 2014-02-21 | |
| US61/942,941 | 2014-02-21 | ||
| US201461974816P | 2014-04-03 | 2014-04-03 | |
| US201461974725P | 2014-04-03 | 2014-04-03 | |
| US201461974785P | 2014-04-03 | 2014-04-03 | |
| US61/974,725 | 2014-04-03 | ||
| US61/974,816 | 2014-04-03 | ||
| US61/974,785 | 2014-04-03 | ||
| PCT/US2014/065742 WO2015077154A1 (en) | 2013-11-20 | 2014-11-14 | Treatment of homozygous familial hypercholesterolemia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017505285A JP2017505285A (ja) | 2017-02-16 |
| JP2017505285A5 true JP2017505285A5 (ja) | 2017-12-21 |
Family
ID=52014370
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016532631A Withdrawn JP2017505285A (ja) | 2013-11-20 | 2014-11-14 | ホモ接合性家族性高コレステロール血症の治療 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20150139987A1 (ja) |
| EP (1) | EP3071198A1 (ja) |
| JP (1) | JP2017505285A (ja) |
| KR (1) | KR20160079124A (ja) |
| CN (1) | CN105764498A (ja) |
| AU (1) | AU2014353246A1 (ja) |
| CA (1) | CA2930069A1 (ja) |
| CL (1) | CL2016001215A1 (ja) |
| EA (1) | EA201691039A1 (ja) |
| HK (1) | HK1224186A1 (ja) |
| IL (1) | IL245748A0 (ja) |
| MX (1) | MX2016006583A (ja) |
| PH (1) | PH12016500886A1 (ja) |
| WO (1) | WO2015077154A1 (ja) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9255154B2 (en) | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
| EP3107540A4 (en) * | 2014-02-17 | 2017-08-30 | Hetero Research Foundation | Polymorphs of lomitapide and its salts |
| US10272058B2 (en) | 2014-03-20 | 2019-04-30 | Cymabay Therapeutics, Inc. | Treatment of intrahepatic cholestatic diseases |
| MX367478B (es) | 2014-03-20 | 2019-08-23 | Cymaby Therapeutics Inc | Tratamiento de enfermedades colestasicas intrahepaticas. |
| KR102374499B1 (ko) | 2014-04-11 | 2022-03-14 | 사이머베이 쎄라퓨틱스, 인코퍼레이티드 | Nafld 및 nash 의 치료 |
| BR102015025502B1 (pt) * | 2015-04-30 | 2022-06-21 | Aegerion Pharmaceuticals, Inc | Composição de lomitapida, tablete, produto de lomitapida, métodos para analisar uma composição de amostra de lomitapida e para determinar uma quantidade de uma impureza em uma amostra da composição |
| WO2017035340A1 (en) * | 2015-08-25 | 2017-03-02 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for treating a proprotein convertase subtilisin kexin (pcsk9) gene-associated disorder |
| CN105481758A (zh) * | 2016-01-13 | 2016-04-13 | 天津药物研究院有限公司 | 一种洛美他派晶型ⅰ及其制备方法和用途 |
| MX2018012741A (es) * | 2016-04-28 | 2019-05-16 | Regeneron Pharma | Metodos para el tratamiento de pacientes con hipercolesterolemia familiar. |
| WO2017200715A1 (en) * | 2016-05-19 | 2017-11-23 | Cymabay Therapeutics, Inc. | Treatment of severe hyperlipidemia |
| US10512622B2 (en) | 2017-07-14 | 2019-12-24 | Cymabay Therapeutics, Inc. | Treatment of intrahepatic cholestatic diseases |
| WO2019101151A1 (zh) * | 2017-11-23 | 2019-05-31 | 浙江海正药业股份有限公司 | 一种海泽麦布和HMG-CoA还原酶抑制剂的药物组合物 |
| US20220040332A1 (en) * | 2018-12-20 | 2022-02-10 | The Trustees Of The University Of Pennsylvania | Gene therapy for treating familial hypercholesterolemia |
| JOP20210193A1 (ar) | 2019-01-18 | 2023-01-30 | Astrazeneca Ab | مثبطات pcsk9 وطرق استخدامها |
| US20210145775A1 (en) | 2019-11-14 | 2021-05-20 | Cymabay Therapeutics, Inc. | Treatment of intestinal barrier dysfunction and associated diseases |
| US20210145774A1 (en) | 2019-11-14 | 2021-05-20 | Cymabay Therapeutics, Inc. | Treatment of alcoholic liver disease |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5739135A (en) | 1993-09-03 | 1998-04-14 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
| US5883109A (en) | 1996-07-24 | 1999-03-16 | Bristol-Myers Squibb Company | Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug |
| US6066653A (en) | 1997-01-17 | 2000-05-23 | Bristol-Myers Squibb Co. | Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs |
| US7407943B2 (en) | 2001-08-01 | 2008-08-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein B expression |
| EP2100877B1 (en) | 2003-09-19 | 2012-01-25 | Janssen Pharmaceutica N.V. | 4-((Phenoxyalkyl)thio)-phenoxyacetic acids and analogs |
| SI1725234T1 (sl) | 2004-03-05 | 2013-04-30 | The Trustees Of The University Of Pennsylvania | Postopki zdravljenja nepravilnosti ali bolezni povezanih s hiperlipidemijo in hiperholesterolemijo z minimiziranjem stranskih uäśinkov |
| JO3006B1 (ar) | 2005-09-14 | 2016-09-05 | Janssen Pharmaceutica Nv | املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك |
| EP2346498B1 (en) * | 2008-10-17 | 2018-12-26 | Cymabay Therapeutics, Inc. | Methods of reducing small, dense ldl particles |
| JOP20200043A1 (ar) * | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
-
2014
- 2014-11-14 US US14/541,835 patent/US20150139987A1/en not_active Abandoned
- 2014-11-14 EA EA201691039A patent/EA201691039A1/ru unknown
- 2014-11-14 KR KR1020167016225A patent/KR20160079124A/ko not_active Application Discontinuation
- 2014-11-14 CA CA2930069A patent/CA2930069A1/en not_active Abandoned
- 2014-11-14 WO PCT/US2014/065742 patent/WO2015077154A1/en active Application Filing
- 2014-11-14 JP JP2016532631A patent/JP2017505285A/ja not_active Withdrawn
- 2014-11-14 EP EP14809184.6A patent/EP3071198A1/en not_active Withdrawn
- 2014-11-14 CN CN201480063803.XA patent/CN105764498A/zh active Pending
- 2014-11-14 MX MX2016006583A patent/MX2016006583A/es unknown
- 2014-11-14 AU AU2014353246A patent/AU2014353246A1/en not_active Abandoned
-
2016
- 2016-05-12 PH PH12016500886A patent/PH12016500886A1/en unknown
- 2016-05-19 IL IL245748A patent/IL245748A0/en unknown
- 2016-05-20 CL CL2016001215A patent/CL2016001215A1/es unknown
- 2016-10-28 HK HK16112450.0A patent/HK1224186A1/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017505285A5 (ja) | ||
| JP2017513836A5 (ja) | ||
| HRP20192299T1 (hr) | Liječenje nafld i nash | |
| JP2017508817A5 (ja) | ||
| CY1119575T1 (el) | Ενωσεις υποκατεστημενης βενζαλδεϋδης και μεθοδοι για τη χρηση τους στην αυξηση της οξυγονωσης του ιστου | |
| CY1120939T1 (el) | Συνδυασμος ρεγοραφενιμπης και ακετυλοσαλικυλικου οξεος για τη θεραπευτικη αντιμετωπιση του ορθοκολικου καρκινου | |
| RS54873B1 (sr) | Policiklična-karbamoilpiridonska jedinjenja i njihova farmaceutska upotreba | |
| JP2015078230A5 (ja) | ||
| JP2014521735A5 (ja) | ||
| PH12016500886A1 (en) | Treatment of homozygous familial hypercholesterolemia | |
| JP2014507446A5 (ja) | ||
| JP2014511891A5 (ja) | ||
| UA109698C2 (xx) | Похідні азаіндазолу або діазаіндазолу як медикамент | |
| WO2015025228A3 (en) | Compositions and therapeutic methods for accelerated plaque regression | |
| EA201301240A1 (ru) | Полиморфная форма бензоата линаглиптина | |
| MX2020010300A (es) | Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas. | |
| JP2016511753A5 (ja) | ||
| JP2016510326A5 (ja) | ||
| EA201490552A1 (ru) | Холиновая соль замещенного циклобутендиона, обладающая противовоспалительной способностью | |
| MX2017002967A (es) | Composicion farmaceutica novedosa que contiene derivado de acido hidroxamico o sal del mismo. | |
| EP3412668A3 (en) | A selective inhibitor of phosphatidylinositol 3-kinase-gamma | |
| NZ602029A (en) | Use of meloxicam for the long-term treatment of kidney disorders in cats | |
| WO2014107730A3 (en) | Use of fatty acid niacin conjugates for treating diseases | |
| JP2015516419A5 (ja) | ||
| EA201692298A1 (ru) | Производные карбоксамидов |